Ülke: Kanada
Dil: İngilizce
Kaynak: Health Canada
SILDENAFIL (SILDENAFIL CITRATE)
ACCEL PHARMA INC
G04BE03
SILDENAFIL
25MG
TABLET
SILDENAFIL (SILDENAFIL CITRATE) 25MG
ORAL
4
Prescription
PHOSPHODIESTERASE TYPE 5 INHIBITORS
Active ingredient group (AIG) number: 0136261001; AHFS:
APPROVED
2018-08-03
_________________________________________________________________________________ _ _ACCEL-SILDENAFIL (sildenafil citrate) Product Monograph _ _Page 1 of 49_ PRODUCT MONOGRAPH PR ACCEL-SILDENAFIL sildenafil as sildenafil citrate Tablets 25 mg, 50 mg and 100 mg House Standard cGMP-Specific Phosphodiesterase Type 5 Inhibitor Treatment of Erectile Dysfunction Accel Pharma Inc. 99 Place Frontenac Pointe-Claire, Quebec H9R 4Z7 Date of Revision: December 27, 2018 SUBMISSION CONTROL NO: 222236 _________________________________________________________________________________ _ _ACCEL-SILDENAFIL (sildenafil citrate) Product Monograph _ _Page 2 of 49_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .............................................................. 3 SUMMARY PRODUCT INFORMATION .......................................................................... 3 INDICATIONS AND CLINICAL USE ................................................................................ 3 CONTRAINDICATIONS ..................................................................................................... 3 WARNINGS AND PRECAUTIONS .................................................................................... 4 ADVERSE REACTIONS ...................................................................................................... 7 DRUG INTERACTIONS .................................................................................................... 12 DOSAGE AND ADMINISTRATION ................................................................................ 15 OVERDOSAGE .................................................................................................................. 16 ACTION AND CLINICAL PHARMACOLOGY .............................................................. 17 STORAGE AND STABILITY ............................................................................................ 20 SPECIAL HANDLING INSTRUCTIONS ......................................................................... 20 DOSAGE FORMS, CO Belgenin tamamını okuyun